Abstract
The successful implementation of any biologically derived product in human clinical trials and as a marketed biopharmaceutical requires the critical utilization of effective viral clearance steps. As biologic products have inherent risks of potentially carrying and or amplifying adventitious viruses that may be present in or introduced into the original materials, a number of processing steps are needed to provide adequate virus removal. Some common process steps are introduced into downstream purification schemes that provide a physical means to separate and/or remove viruses from the therapeutic protein. The physical steps often include virus-removing filters and chromatographic resins in column or membrane configurations, but can also include the introduction of irradiation, high heat steps, or other means for destroying the infectivity of a virus. Chemical treatment steps are often utilized as a means to inactivate a wide variety of virus types.
A general overview is provided that describes the most commonly used techniques for virus removal or inactivation for the validation of virus clearance. Data sets from studies performed at WuXi AppTec for a wide variety of biologics reveal a number of steps that provide guidance for the design of process steps dedicated to viral clearance. The overall efficiency of several process steps reveals a number of efficient, robust steps, such as nanofiltration which can be designed for removal of almost all viral species. Exposure to a low pH or solvent detergent is also a robust step for inactivating enveloped virus. Steps with greater variances in predictability include chromatography steps such as capture columns and anion exchange resins. A lower removal capacity is typically expected for other chromatography steps such as cation exchange steps.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) (1997). “Points to consider in the manufacture and testing of monoclonal antibody products for human use.” 94D-0259
US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) (1993) “Points to consider in the characterization of cell lines used to produce biologicals”
Committee for Proprietary Medicinal Products (CPMP) (1997) “International conference on harmonization (ICH) Topic Q 5 A. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.” Consensus Guideline ICH Viral Safety Document: Step 4. CPMP/ICH/295/95
Committee for Proprietary Medicinal Products (CPMP) (1996) “The design, contribution and interpretation of studies validating the inactivation and removal of viruses.” CPMP/BWP/268/95
European Medicines Agency (EMEA) (2009) “Guideline on virus safety evaluation of biotechnological investigational medicinal products.” EMEA/CHMP/BWP/398498
American National Standard (2007). “Medical devices utilizing animal tissues and their derivatives—Part 3: validation of the elimination and/or inactivation of viruses.” ANSI/AAMI/ISO 22442-3
Garnick RL (1996) Experience with viral contamination in cell culture. Dev Biol Stand 88:49–56
Skrine J (2010) A biotech production facility contamination case study—Minute virus of mice. Presented at PDA/FDA adventitious viruses in biologics: detection and mitigation strategies workshop. Bethesda, MD, 1–3 Dec
Moody M (2010) MVM contamination—A case study: detection, root cause determination and corrective actions, at merrimack pharmaceuticals. Presented at PDA/FDA adventitious viruses in biologics: detection and mitigation strategies workshop. Bethesda, MD, 1–3 Dec
Jones N (2010) Identification and remediation of a cell culture virus contamination, at genzyme. Presented at PDA/FDA adventitious viruses in biologics: detection and mitigation strategies workshop. Bethesda, MD, 1–3 Dec
Pierard I (2010) Contamination by porcine circo virus: findings, investigations and learning, at GSK. Presented at PDA/FDA adventitious viruses in biologics: detection and mitigation strategies workshop. Bethesda, MD, 1–3 Dec
Norling L (2011) Virus inactivation and application of the modular approach. Presented at IBC’s 8th international conference viral safety for biologicals. Orlando, FL, 24–25 Feb
Floyd R, Sharp DG (1978) Viral aggregation: effects of salts on the aggregation of poliovirus and reovirus at low pH. Appl Environ Microbiol 35:1084–1094
Zhou J (2008) Methods for removing viral contaminants during protein purification. United States Patent Application Publication. Pub. No.: US 2008/0132688 A1. Pub. Date: 5 Jun
Brorson K, Krejci S, Lee K, Hamilton E, Stein K, Yuan Xu (2003) Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol Bioeng 82: 321–329
Brough H, Antoniou C, Carter J, Jakubik J, Xu Y, Lutz H (2002) Performance of a novel Viresolve NFR virus filter. Biotechnol Prog 18: 782–795
Gottschalk U (2009) Process scale purification of antibodies (Chapters 4, 7, 8, 9). Wiley, Hoboken, NJ
Lute S et al (2008) Robustness of virus removal by Protein A chromatography is independent of media lifetime. J Chromatogr A 1205:17–25
Technical Report No. 47 (2010) Preparation of virus spikes used for viral clearance studies. Parenteral Drug Association (PDA) Bethesda, MD
Technical Report No. 41 (2008) Virus filtration. Parenteral Drug Association (PDA) Bethesda, MD
Cherney B (2010) Application of quality of design in the control of adventitious viruses: gaps in the current processes in the prevention of virus contaminants. PDA/FDA adventitious viruses in biologics: detection and mitigation strategies workshop. Bethesda, MD, 1–3 Dec
Norling L et al (2005) Impact of multiple re-use of anion exchange chromatography media on virus removal. J Chromatogr A 1069:79–89
Strauss D et al (2010) Strategies for developing design spaces for viral clearance by anion exchange chromatography during monoclonal antibody production. Biotechnol Prog 26: 750–755
Strauss D et al (2009) Understanding the mechanism of virus removal by Q Sepharose fast flow chromatography during the purification of CHO-cell derived biotherapeutics. Biotechnol Bioeng 104:371–380
Miesegaes G, Lute S, Brorson K (2010) Analysis of viral clearance unit operations for monoclonal antibodies. Biotechnol Bioeng 106:238–246
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Cipriano, D., Burnham, M., Hughes, J.V. (2012). Effectiveness of Various Processing Steps for Viral Clearance of Therapeutic Proteins: Database Analyses of Commonly Used Steps. In: Voynov, V., Caravella, J. (eds) Therapeutic Proteins. Methods in Molecular Biology, vol 899. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-921-1_18
Download citation
DOI: https://doi.org/10.1007/978-1-61779-921-1_18
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-920-4
Online ISBN: 978-1-61779-921-1
eBook Packages: Springer Protocols